A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605533822 | ||
| 003 | CHVBK | ||
| 005 | 20210128100840.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-015-9428-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-015-9428-y | ||
| 245 | 0 | 2 | |a A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times |h [Elektronische Daten] |c [Jonathan Knights, Shashank Rohatagi] |
| 520 | 3 | |a Although there is a body of literature focused on minimizing the effect of dosing inaccuracies on pharmacokinetic (PK) parameter estimation, most of the work centers on missing doses. No attempt has been made to specifically characterize the effect of error in reported dosing times. Additionally, existing work has largely dealt with cases in which the compound of interest is dosed at an interval no less than its terminal half-life. This work provides a case study investigating how error in patient reported dosing times might affect the accuracy of structural model parameter estimation under sparse sampling conditions when the dosing interval is less than the terminal half-life of the compound, and the underlying kinetics are monoexponential. Additional effects due to noncompliance with dosing events are not explored and it is assumed that the structural model and reasonable initial estimates of the model parameters are known. Under the conditions of our simulations, with structural model CV% ranging from ~20 to 60%, parameter estimation inaccuracy derived from error in reported dosing times was largely controlled around 10% on average. Given that no observed dosing was included in the design and sparse sampling was utilized, we believe these error results represent a practical ceiling given the variability and parameter estimates for the one-compartment model. The findings suggest additional investigations may be of interest and are noteworthy given the inability of current PK software platforms to accommodate error in dosing times. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Population pharmacokinetics |2 nationallicence | |
| 690 | 7 | |a Simulation |2 nationallicence | |
| 690 | 7 | |a Dosing inaccuracies |2 nationallicence | |
| 690 | 7 | |a Reporting error |2 nationallicence | |
| 690 | 7 | |a Parameter Estimation |2 nationallicence | |
| 700 | 1 | |a Knights |D Jonathan |u Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Blvd. Suite 300, 08540, Princeton, NJ, USA |4 aut | |
| 700 | 1 | |a Rohatagi |D Shashank |u Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Blvd. Suite 300, 08540, Princeton, NJ, USA |4 aut | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/6(2015-12-01), 627-637 |x 1567-567X |q 42:6<627 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-015-9428-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-015-9428-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Knights |D Jonathan |u Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Blvd. Suite 300, 08540, Princeton, NJ, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Rohatagi |D Shashank |u Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Blvd. Suite 300, 08540, Princeton, NJ, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/6(2015-12-01), 627-637 |x 1567-567X |q 42:6<627 |1 2015 |2 42 |o 10928 | ||